Work

A phase I/II, multicenter, open-label study of REGN5668 (mucin [MUC]16 x CD28 bispecific antibody [bsAb]) with cemiplimab (programmed death [PD]-1 Ab) or REGN4018 (MUC16 x CD3 bsAb) in recurrent ovarian cancer (rOVCA).

Year: 2021

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2021.39.15_suppl.tps5602

Authors: Ira Seth Winer, Anthony Frank Shields, Oladapo O. Yeku, Joyce F. Liu, Mary Jane Peterman, Suk Young Yoo, Israel Lowy, N. Alice Yama-Dang, Priscila Hermont Goncalves, Glenn Kroog

Institutions: Wayne State University, The Barbara Ann Karmanos Cancer Institute, Massachusetts General Hospital, Dana-Farber Cancer Institute, Regeneron (United States)

Language: English

Topic: Ovarian cancer diagnosis and treatment

Subfield: Reproductive Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W3166879347

Cites:

Cited by: 5

Related to: 10